New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareFollistatin 344 vs Ovagen

Follistatin 344 vs Ovagen

Side-by-side comparison of key properties, dosing, and research.

Anabolic & IGF
Follistatin 344
Anti-Aging & Longevity
Ovagen
Summary
Follistatin 344 is a recombinant form of the endogenous follistatin protein. It inhibits myostatin and activin — the primary negative regulators of muscle growth — potentially removing the genetic ceiling on muscle development. It is one of the most theoretically powerful anabolic compounds but is experimental with limited human data.
Ovagen is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, primarily targeting liver tissue. It supports hepatocyte function, liver cell regeneration, and protection against hepatic aging and disease. Ovagen is used in protocols for chronic liver disease, hepatoprotection, and metabolic liver conditions including fatty liver disease.
Half-Life
~24–36 hours
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ, IM
SubQ, Oral
Research
Typical Dose
100 mcg
10 mg per day
Frequency
Once daily
Daily for 10–30 days
Key Benefits
  • Inhibits myostatin — removes muscle growth ceiling
  • Significant increases in muscle mass and strength
  • Reduces fat mass
  • Promotes bone density
  • May stimulate hair follicle cycling
  • Anti-fibrotic effects in muscle tissue
  • Synergistic with IGF-1 and other anabolic peptides
  • Hepatoprotective effects against toxic, viral, and metabolic liver damage
  • Promotes hepatocyte regeneration and liver tissue repair
  • May reduce liver fibrosis progression
  • Supports liver metabolic function and detoxification capacity
  • Anti-aging effects on hepatic tissue
  • Useful in NAFLD/MASH supportive protocols
  • Compatible with NAD+, glutathione, and BPC-157 in liver health stacks
Side Effects
  • Muscle soreness (from rapid hypertrophy)
  • Potential reproductive effects (activin inhibition)
  • Unknown long-term safety profile
  • Possible esophageal effects at high doses (animal data)
  • Generally well tolerated
  • Mild injection site reactions
  • No clinically significant hepatotoxicity reported
Stacks With